• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

    8/29/23 8:00:00 AM ET
    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNLI alert in real time by email

    CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as Growth Partner. In this role, he will help scale and grow several Flagship-founded companies, working together with leaders at Flagship and its ecosystem of companies on organizational development, long-term strategy, financing, and business development.

    David Khougazian

    Khougazian joins Flagship from Sanofi where he spent over two decades most recently leading Sanofi's engagement in global emerging markets including China, Eurasia, Latin America, and the Middle East. He also served as the CEO of Sanofi Pasteur MSD, a joint venture between Sanofi and Merck, and was previously Chief of Staff to the Sanofi CEO, leading the company's Transformation Office and serving as a member of the Executive Committee and Global Leadership Team. Prior to joining Sanofi, he was Vice President and Head of Mergers and Acquisitions at Aventis Pharmaceuticals and started his career at HSBC where he managed a portfolio of diversified financial assets.

    "David has deep experience developing and advancing healthcare companies by harnessing innovation partnerships," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering. "I am pleased to welcome David to our team to help progress our companies as they create value and growth."

    "I am excited to join Flagship Pioneering and its growing ecosystem in revolutionizing the innovation process in health and developing platforms to address huge patient need," said David Khougazian, Growth Partner, Flagship Pioneering. "As part of Flagship's leadership team, I look forward to applying my experience in biopharma to scaling and growing Flagship's innovative bioplatform companies."

    About David Khougazian

    David brings more than 25 years of leadership experience in the global healthcare industry including over two decades at Sanofi where he held a diverse set of responsibilities during his tenure. He most recently led Sanofi's work in global emerging markets including China, Eurasia, Latin America and the Middle East. He also served as the CEO of Sanofi Pasteur MSD, a joint venture between Sanofi and Merck, and was previously Chief of Staff to the Sanofi CEO, leading Sanofi's Transformation Office and serving as a member of the Executive Committee and Global Leadership Team.

    Prior to joining Sanofi, David was Vice President and Head of Mergers and Acquisitions at Aventis Pharmaceuticals, a company he participated in creating as part of his finance and corporate development work at Rhône-Poulenc. David started his career at HSBC where he managed a portfolio of diversified financial assets.

    David is an engineer by training and graduated from ENSAE and holds an MBA from the Collège des Ingénieurs.

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. To date, Flagship has deployed over $3.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $26 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 44 transformative companies, including Denali Therapeutics (NASDAQ:DNLI), Foghorn Therapeutics (NASDAQ:FHTX), Generate Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ:MRNA), Omega Therapeutics (NASDAQ:OMGA), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB) and Tessera Therapeutics.

    CONTACT: press@flagshippioneering.com

    (PRNewsfoto/Flagship Pioneering)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-announces-appointment-of-david-khougazian-as-growth-partner-301911946.html

    SOURCE Flagship Pioneering

    Get the next $DNLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNLI
    $FHTX
    $MCRB
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Denali Therapeutics Inc.
    $DNLI
    1/7/2026$25.00Buy
    UBS
    Foghorn Therapeutics Inc.
    $FHTX
    12/18/2025$11.00Buy
    BTIG Research
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Foghorn Therapeutics Inc.
    $FHTX
    11/7/2025$12.00Buy
    Guggenheim
    Sana Biotechnology Inc.
    $SANA
    9/24/2025$5.00Outperform
    Wedbush
    Foghorn Therapeutics Inc.
    $FHTX
    9/17/2025$10.00Buy
    B. Riley Securities
    Sana Biotechnology Inc.
    $SANA
    7/3/2025$12.00Overweight
    Morgan Stanley
    More analyst ratings

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Moderna with a new price target

    UBS resumed coverage of Moderna with a rating of Neutral and set a new price target of $34.00

    1/7/26 9:12:19 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Denali Therapeutics with a new price target

    UBS resumed coverage of Denali Therapeutics with a rating of Buy and set a new price target of $25.00

    1/7/26 8:37:43 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BTIG Research initiated coverage on Foghorn Therapeutics with a new price target

    BTIG Research initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $11.00

    12/18/25 9:11:03 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

    Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer on track to be IND-ready in 2026 Selective EP300 degrader program shows preclinical superior anti-tumor efficacy and tolerability over dual CBP/EP300; tracking to IND-enabling studies in 2026 Strong balance sheet with cash, cash equivalents, and marketable securities

    1/9/26 10:20:09 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

    SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of the presentation will be available at the same location for 30 days following the conference. About Sana BiotechnologySana Biotechnology, In

    1/7/26 4:26:32 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

    Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali's TransportVehicle™ (TV)-enabled investigational therapy for Hunter syndromeExpecting multiple clinical data readouts from pipeline programs including for Sanfilippo syndrome Type A (ETV:SGSH), granulin-related frontotemporal dementia (PTV:PGRN) and Parkinson's disease (LRRK2 inhibitor)Planning for initiation of first-in-human clinical studies with TV-enabled therapeutics for Alzheimer's disease (OTV:MAPT, ATV:Abeta) and Pompe disease (ETV:GAA)Continuing to strengthen leadership in transferrin receptor (TfR)-enabled and blood-brain barrier crossing therapeutics with continued advancement of enzyme, oligonucleotide

    1/6/26 8:00:00 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Watts Ryan J. sold $580,767 worth of shares (35,198 units at $16.50), decreasing direct ownership by 11% to 296,833 units (SEC Form 4)

    4 - Denali Therapeutics Inc. (0001714899) (Issuer)

    1/8/26 4:20:05 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    COFO and Secretary Schuth Alexander O. sold $284,097 worth of shares (17,218 units at $16.50), decreasing direct ownership by 6% to 282,828 units (SEC Form 4)

    4 - Denali Therapeutics Inc. (0001714899) (Issuer)

    1/8/26 4:19:45 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 780 shares, increasing direct ownership by 2% to 43,872 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    1/6/26 4:36:50 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/12/24 5:46:20 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

    For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

    4/26/23 6:04:21 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    SEC Filings

    View All

    SEC Form 144 filed by Denali Therapeutics Inc.

    144 - Denali Therapeutics Inc. (0001714899) (Subject)

    1/6/26 8:25:34 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Denali Therapeutics Inc. (0001714899) (Filer)

    1/6/26 8:02:38 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moderna Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Moderna, Inc. (0001682852) (Filer)

    1/5/26 9:04:27 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 5:12:32 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 6:00:14 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/12/24 4:52:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

    Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advancement of Seres' portfolio, including Phase 2-ready lead candidate SER-155 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced the publication of two manuscripts in Nature Medicine and the Journal of Infectious Diseases highlighting new insights into the functional mechanism and clinical impact of VOWST™. Together, these publications provide further va

    1/6/26 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

    Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on trackDNL126 Phase 1/2 study enrollment completed, supporting an accelerated approval path in MPS IIIATwo new regulatory applications submitted to initiate clinical studies with DNL628 (OTV:MAPT) for Alzheimer's disease and DNL952 (ETV:GAA) for Pompe diseaseTim Van Hauwermeiren, CEO of argenx, to join Denali's Board of DirectorsCarole Ho, M.D., Chief Medical Officer, departing company; Peter Chin, M.D., assuming role of Acting CMO and Head of DevelopmentDenali to host Investor Day on December 4, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 0

    11/6/25 4:01:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Announces Board and Executive Leadership Updates

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali's Board of Directors. Mr. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx. Carole Ho, M.D., who has served as Denali's Chief Medical Officer and Head of Development since 2015, will be departing to join Eli Lilly and Company as Executive Vice President, and President of Lilly Neuroscience. Peter Chin, M.D., is assuming the role of Acting Chief Medical Officer and Head of Development at Denali. Dr. Chin is a neurologist and joined Denali in

    11/6/25 4:00:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Financials

    Live finance-specific insights

    View All

    Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

    NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Denali Therapeutics, Inc. (NASDAQ:DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali's lead investigational TransportVehicleTM-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). A Biologics License Application (BLA) for accelerated approval of tividenofusp alfa is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target date of April 5, 2026. "We are delighted t

    12/4/25 7:10:00 AM ET
    $DNLI
    $RPRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

    SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) and Royalty Pharma plc (NASDAQ:RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali's lead investigational TransportVehicle™-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). A Biologics License Application (BLA) for accelerated approval of tividenofusp alfa is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target date of April 5, 2026. "We are pleased t

    12/4/25 7:00:00 AM ET
    $DNLI
    $RPRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint related enterocolitis expected to inform broader SER-155 opportunity; initial study results anticipated in early 2026 Seres recently implemented actions to reduce operating costs; based on these

    11/5/25 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care